Search research articles
Contact Us
Filters
Showing results (791-800 of 903) with videos related to
Page
of 91
Sort By:
The Lancet. Oncology
|
December 17, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
Susan O'Brien, Richard R Furman, Steven E Coutre, et al.
Leukemia & Lymphoma
|
February 28, 2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997
David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.
Blood Advances
|
September 30, 2024
CD37 in acute myeloid leukemia: a novel surface target for drug delivery
Erin Jeremy, Esthela Artiga, Sara Elgamal, et al.
Journal of Geriatric Oncology
|
June 17, 2023
Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia
P Connor Johnson, Jennifer A Woyach, Angela Ulrich, et al.
Blood Advances
|
January 17, 2020
Clinical and functional significance of circular RNAs in cytogenetically normal AML
Dimitrios Papaioannou, Stefano Volinia, Deedra Nicolet, et al.
Cancer Discovery
|
August 4, 2022
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation
Anna Yeaton, Geraldine Cayanan, Sanam Loghavi, et al.
Leukemia
|
April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
Richard R Furman, John C Byrd, Roger G Owen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C Byrd, Peter Hillmen, Paolo Ghia, et al.
Blood
|
February 5, 2009
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
David M Lucas, Ryan B Edwards, Gerard Lozanski, et al.
The New England Journal of Medicine
|
June 21, 2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
John C Byrd, Richard R Furman, Steven E Coutre, et al.
Page
of 91
Search research articles
Search
Showing results (791-800 of 903) with videos related to
Sort By:
Page
of 91
The Lancet. Oncology
|
December 17, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
Susan O'Brien, Richard R Furman, Steven E Coutre, et al.
Leukemia & Lymphoma
|
February 28, 2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997
David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.
Blood Advances
|
September 30, 2024
CD37 in acute myeloid leukemia: a novel surface target for drug delivery
Erin Jeremy, Esthela Artiga, Sara Elgamal, et al.
Journal of Geriatric Oncology
|
June 17, 2023
Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia
P Connor Johnson, Jennifer A Woyach, Angela Ulrich, et al.
Blood Advances
|
January 17, 2020
Clinical and functional significance of circular RNAs in cytogenetically normal AML
Dimitrios Papaioannou, Stefano Volinia, Deedra Nicolet, et al.
Cancer Discovery
|
August 4, 2022
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation
Anna Yeaton, Geraldine Cayanan, Sanam Loghavi, et al.
Leukemia
|
April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
Richard R Furman, John C Byrd, Roger G Owen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C Byrd, Peter Hillmen, Paolo Ghia, et al.
Blood
|
February 5, 2009
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
David M Lucas, Ryan B Edwards, Gerard Lozanski, et al.
The New England Journal of Medicine
|
June 21, 2013
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
John C Byrd, Richard R Furman, Steven E Coutre, et al.
Page
of 91